利拉鲁肽对2型糖尿病患者异位脂肪堆积的安慰剂对照随机试验
本文为MAGNA VICTORIA研究的预设亚分析,50例BMI>25 kg/m2的2型糖尿病患者随机接受利拉鲁肽1.8 mg每日一次或安慰剂治疗26周。结果显示利拉鲁肽显著降低体重和腹部皮下脂肪,但未显著改变内脏、心外膜、肝脏及心肌甘油三酯含量。
要点
- 利拉鲁肽26周显著降低体重,估计疗效差为-4.5 kg。
- 利拉鲁肽主要减少皮下脂肪,对内脏脂肪无显著影响。
- 心外膜脂肪、肝脏及心肌甘油三酯含量组间无显著差异。
核心结论
- 与安慰剂相比,利拉鲁肽治疗者体重下降更显著,主要减少皮下脂肪,而非内脏、肝脏、心肌或心外膜脂肪。
研究设计与样本
- MAGNA VICTORIA研究的预设亚分析,单中心平行组试验,50例BMI>25 kg/m2的2型糖尿病患者按1:1随机分配,按性别和胰岛素使用分层,接受利拉鲁肽1.8 mg每日一次或安慰剂26周,叠加标准治疗,参与者、研究者和结局评估者均设盲。
主要发现
- 利拉鲁肽组体重从98.4±13.8 kg降至94.3±14.9 kg,安慰剂组从94.5±13.1 kg降至93.9±13.2 kg,估计疗效差-4.5(95%CI -6.4, -2.6)kg。
- HbA1c两组均下降,但利拉鲁肽 vs 安慰剂的估计疗效差为-2.9(95%CI -8.1, 2.3)mmol/mol或-0.3(95%CI -0.8, 0.2)%,无显著差异。
- 内脏脂肪组间无显著变化,估计疗效差-7(95%CI -24, 10)cm2;皮下脂肪利拉鲁肽组减少更显著,估计疗效差-29(95%CI -51, -8)cm2。
- 心外膜脂肪估计疗效差0.2(95%CI -1.5, 1.8)cm2,肝脏甘油三酯含量估计疗效差-2.1(95%CI -5.3, 1.0)%,心肌甘油三酯含量估计疗效差-0.1(95%CI -0.4, 0.2)%,均无显著差异。
- 未发生经裁定的严重不良事件。
临床怎么用
- 对BMI>25 kg/m2的2型糖尿病患者,利拉鲁肽1.8 mg每日一次治疗26周可显著减重并减少皮下脂肪,但对内脏及异位脂肪沉积的改善有限,临床决策时应结合以异位脂肪为靶点的治疗目标综合评估。
局限性
- 本研究为单中心、样本量较小的次要终点分析,未来需更大规模研究证实结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this work was to assess the effect of liraglutide on ectopic fat accumulation in individuals with type 2 diabetes mellitus. METHODS: This study is a pre-specified subanalysis of the MAGNetic resonance Assessment of VICTOza efficacy in the Regression of cardiovascular dysfunction In type 2 diAbetes mellitus (MAGNA VICTORIA) study, with primary endpoints being the effects of liraglutide on left ventricular diastolic and systolic function. The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care. Participants, study personnel and outcome assessors were blinded to treatment allocation. The secondary endpoints of visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT) and epicardial fat were measured with MRI. Hepatic triacylglycerol content (HTGC) and myocardial triacylglycerol content (MTGC) were quantified with proton MR spectroscopy. Between-group differences (change from baseline) were tested for significance using ANCOVA. Mean differences with 95% CIs were reported. RESULTS: The trial was completed in 2016. Twenty-four participants were randomised to receive liraglutide and 26 to receive placebo. One patient in the liraglutide group withdrew consent before having received the study drug and was not included in the intention-to-treat analysis. Liraglutide (n = 23) vs placebo (n = 26) significantly reduced body weight (liraglutide 98.4 ± 13.8 kg to 94.3 ± 14.9 kg; placebo 94.5 ± 13.1 kg to 93.9 ± 13.2 kg; estimated treatment effect -4.5 [95% CI -6.4, -2.6] kg). HbA1c declined in both groups without a significant treatment effect of liraglutide vs placebo (liraglutide 66.7 ± 11.5 mmol/mol to 55.0 ± 13.2 mmol/mol [8.4 ± 1.1% to 7.3 ± 1.2%]; placebo 64.7 ± 10.2 mmol/mol to 56.9 ± 6.9 mmol/mol [8.2 ± 1.0% to 7.5 ± 0.7%]; estimated treatment effect -2.9 [95% CI -8.1, 2.3] mmol/mol or -0.3 [95% CI -0.8, 0.2]%). VAT did not change significantly between groups (liraglutide 207 ± 87 cm2 to 203 ± 88 cm2; placebo 204 ± 63 cm2 to 200 ± 55 cm2; estimated treatment effect -7 [95% CI -24, 10] cm2), while SAT was reduced by a significantly greater extent with liraglutide than with placebo (liraglutide 361 ± 142 cm2 to 339 ± 131 cm2; placebo 329 ± 107 cm2 to 333 ± 125 cm2; estimated treatment effect -29 [95% CI -51, -8] cm2). Epicardial fat did not change significantly between groups (liraglutide 8.9 ± 4.3 cm2 to 9.1 ± 4.7 cm2; placebo 9.6 ± 4.1 cm2 to 9.6 ± 4.6 cm2; estimated treatment effect 0.2 [95% CI -1.5, 1.8] cm2). Change in HTGC was not different between groups (liraglutide 18.1 ± 11.2% to 12.0 ± 7.7%; placebo 18.4 ± 9.4% to 14.7 ± 10.0%; estimated treatment effect -2.1 [95% CI -5.3, 1.0]%). MTGC was not different after treatment with liraglutide (1.5 ± 0.6% to 1.2 ± 0.6%) vs placebo (1.3 ± 0.5% to 1.2 ± 0.6%), with an estimated treatment effect of -0.1 (95% CI -0.4, 0.2)%. There were no adjudicated serious adverse events. CONCLUSIONS/INTERPRETATION: Compared with placebo, liraglutide-treated participants lost significantly more body weight. Liraglutide primarily reduced subcutaneous fat but not visceral, hepatic, myocardial or epicardial fat. Future larger studies are needed to confirm the results of this secondary endpoint study. TRIAL REGISTRATION: ClinicalTrials.gov NCT01761318. FUNDING: This study was funded by Novo Nordisk A/S (Bagsvaerd, Denmark).
引用
- Bizino MB, Jazet IM, de Heer P, et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia. 2019. PMID: 31690988. doi:10.1007/s00125-019-05021-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。